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TAMING THE PERFECT POISON:  
A COMPARATIVE ANALYSIS OF THE  
EMEA’S EPAR SYSTEM AND THE FDA’S 
IMPROVED WARNING PROTOCOL 
Nicholas R. Kennedy* 
Abstract: In Europe and the United States, regulatory agencies responsi-
ble for monitoring drug safety have struggled to address the health con-
cerns raised by the burgeoning market for minimally invasive cosmetic 
procedures utilizing botulinum toxins, the active ingredients in Botox. A 
2005 study published in the Journal of the American Academy of Dermatology 
drew attention to these shortcomings after an analysis of adverse event 
reports submitted to the Food and Drug Administration (FDA) linked 
twenty-eight patient deaths to Botox-induced respiratory arrest and myo-
cardial infarction. After an independent review of adverse effects reports 
submitted to the European Medicines Agency (EMEA) revealed similar 
findings in Europe, the FDA and EMEA implemented bolstered product 
warnings aimed at increasing patient awareness of the drug’s health risks. 
This Note compares the FDA and EMEA’s heightened warning protocols 
and argues that the agencies’ recent efforts are unlikely to reduce the 
number of serious adverse events linked to botulinum toxins. 
Introduction 
 The demand for minimally invasive cosmetic procedures utilizing 
botulinum toxins—the active ingredients in Botox—has exploded dur-
ing the past decade in North America and Europe.1 Nevertheless, at 
home and abroad, regulatory agencies charged with ensuring drug 
safety have struggled to address the health concerns associated with this 
                                                                                                                      
* Nicholas R. Kennedy is a Staff Member for the Boston College International & Compara-
tive Law Review. 
1 See Millennium Res. Group, European Markets for Facial Aesthetics 2008 54–73 
(2008); Press Release, Millennium Res. Group, Botox and Dermal Fillers Will Be Used by 
More than 6 Million Americans by 2011 (Feb. 7, 2007), available at http://www.mrg.net/ 
News-and-Events/Press-Releases/BOTOX-AND-DERMAL-FILLERS-WILL-BE-USED-BY-MORE- 
THAN.aspx. 
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nascent area of medicine.2 In 2005, a study published in the Journal of 
the American Academy of Dermatology (Coté Study) drew attention to these 
shortcomings after an analysis of adverse event reports submitted to the 
Food and Drug Administration (FDA) linked twenty-eight deaths to 
Botox-induced respiratory arrest and myocardial infarction.3 On the 
heels of this study, government watchdog groups petitioned the Agency 
to take stronger measures to protect patients.4 In 2009, the FDA re-
sponded by implementing a bolstered warning protocol mimicking the 
advisory system used by the European Medicines Agency (EMEA), the 
FDA’s European counterpart.5 
 It is unclear whether the FDA’s recent efforts are sufficient to deal 
with the crisis currently facing the cosmetic medicine industry.6 Botuli-
num toxins are the deadliest naturally occurring substances in the 
world.7 Improperly injected, botulinum toxins can cause severe life-
threatening complications.8 Nonetheless, regulations governing who 
may perform such injections are quite lax.9 In the United States, Botox 
                                                                                                                      
2 See Bridget M. Kuehn, Botox Risks Under Review, 299 JAMA 1417, 1417 (2008); Con-
stanze Löffler, Die Heilsame Giftspritze, Focus, Sept. 1, 2008, at 36; Lauran Neergaard, Health 
Canada Reviews Safety of Botox After Deaths Reported, Toronto Star, Feb. 9, 2008, at A02. 
3 See Timothy R. Coté et al., Botulinum Toxin A Injections: Adverse Events Reported to the US 
Food and Drug Administration in Therapeutic and Cosmetic Cases, 53 J. Am. Acad. Dermatol-
ogy 407, 409 (2005). 
4 See, e.g., Press Release, Pub. Citizen Health Res. Group, Petition to the FDA Request-
ing Regulatory Action Concerning the Possible Spread of Botulinum Toxin (Botox, Myob-
loc) from the Site of Injection to Other Parts of the Body (HRG Publication #1834) ( Jan. 
23, 2008), available at http://www.citizen.org/publications/release.cfm?ID=7559. 
5 See id.; Bridget M. Kuehn, FDA Requires Black Box Warnings on Labeling for Botulinum 
Toxin Products, 301 JAMA 2316, 2316 (2009). 
6 See generally Peter Conrad, The Pursuit of Perfection: The Promise and Perils of Medical En-
hancement, 292 JAMA 867 (2004) (concluding that regulatory agencies have ignored health 
risks associated with the cosmetic medicine industry). 
7 See Carl Lamanna, The Most Poisonous Poison, 130 Sci. 763, 766 (1969) (observing that 
“other protein poisons, such as diphtheria toxin and animal venoms, are hundreds and 
tens of thousands of times less poisonous” than botulinum toxins); Robert Schechter, Ex-
treme Potency of Botulinum Toxin, 355 Lancet 237, 237 (2005). 
8 See, e.g., Daniel S. Chertow et al., Botulism in 4 Adults Following Cosmetic Injections with 
an Unlicensed, Highly Concentrated Botulinum Preparation, 296 JAMA 2476, 2476, 2478 (2006). 
9 See Med. Bd. of Cal., Use of Mid-level Practitioners for Laser, Dermabrators, 
Botox, and Other Treatments, Action Report 1, 9 (2006); Memorandum from the 
Meds. and Healthcare Regulatory Agency on the Supply and Admin. of Botox, Vistabel, Dys-
port and Other Injectable Medicines in Cosmetic Procedures ( Jan. 10, 2008), available at 
http://www.mhra.gov.uk/Howweregulate/index.htm (follow “Medicines” hyperlink; then 
follow “Availability, Prescribing, Selling and Supplying of Medicines” hyperlink; then follow 
“Frequently Raised Issues” hyperlink; then follow “Botox, Vistabel, Dysport and Other In-
jectable Medicines in Cosmetic Procedures” hyperlink) [hereinafter MHRA Botox]; Memo-
randum from Mo. Bd. of Registration for the Healing Arts on Med. Spas, Lasers, and Botox 
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may be injected by non-physician practitioners in the absence of direct 
doctor supervision.10 In Great Britain, the Medicines and Healthcare 
Products Regulatory Agency even permits patients to perform self-
administered injections.11 
 This Note compares and evaluates the adequacy of safety regula-
tions imposed by the FDA and EMEA on manufacturers of botulinum 
toxin products. In particular, this Note addresses the sufficiency of the 
FDA’s improved warning protocol as a method of reducing the inci-
dence of serious adverse events related to botulinum toxin type A (Bo-
tox). Part I traces the history of botulinum toxin use and its emergence 
as a drug for cosmetic indications. Part II discusses the Coté Study’s in-
dependent review of adverse event reports submitted to the FDA in 
connection with botulinum toxin type A. This section also canvasses the 
EMEA’s European Public Assessment Report (EPAR) advisory system 
and the EMEA’s response to seventeen reported deaths in European 
Union (EU) member states linked to botulinum toxin products. Fur-
thermore, Part II examines the FDA’s new warning protocol vis-à-vis bo-
tulinum toxin products as a response to criticism that the FDA lagged 
behind its European counterpart. Part III compares the FDA’s strength-
ened warning protocol to the advisory system employed by the EMEA 
and evaluates whether the improved protocol can reduce the number of 
serious adverse events in the United States. Finally, Part III proposes an 
alternative approach toward reducing the number of serious adverse 
events that relies on state-based regulatory action by medical licensing 
boards. 
I. Background 
 Nineteenth-century physician Justinus Kerner first examined the 
effects of botulinum toxin after he identified more than two hundred 
cases of botulism12 attributed to the ingestion of inadequately pre-
                                                                                                                      
( Jul. 1, 2009), available at http://www.pr.mo.gov/boards/healingarts/Medical-Spas-Lasers- 
Botox.pdf [hereinafter MBRHA Memo]. 
10 See Med. Bd. of Cal., supra note 9, at 1, 9; MBRHA Memo, supra note 9. 
11 See MHRA Botox, supra note 9. 
12 Botulism, “a paralytic disease caused by [the] potent neurotoxin . . . Clostridium botu-
linum,” is separated into three distinct cases: (1) food-borne botulism, caused by the inges-
tion of food contaminated with C. botulinum; (2) wound botulism, which develops in 
wounds infected with the toxin; and (3) intestinal botulism, caused by “ingestion of spores 
and production of [the] toxin in the intestines” of infected individuals. Elias Abrutyn, 
Botulism, in Harrison’s Principles of Internal Medicine 841, 842 (16th ed. 2005). All 
incidences of the disease “begin[] with cranial nerve involvement,” with paralytic symp-
toms gradually spreading to the extremities. Id. 
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served blood sausages.13 In an 1817 monograph, Kerner suggested the 
toxin had potential therapeutic use in blocking abnormal motor 
movements and eliminating hypersecretion after observing its paralytic 
effect on the eye muscles and secretory glands.14 In the same mono-
graph, however, Kerner expressed doubt over the tenability of such ap-
plications, hypothesizing that the toxin’s extreme lethality would make 
it difficult to manage in a clinical setting.15 
 In 1989, the FDA approved botulinum toxin type A (BTX-A) for 
the treatment of adult strabismus (crossed eyes) and blepharospasm 
(eyelid tics) after a decade’s worth of data demonstrated BTX-A’s posi-
tive effect in eliminating eyelid and hemifacial spasms.16 Shortly there-
after, ophthalmologists noticed that blepharospasm patients injected 
with BTX-A around the eyes and upper face at intervals of three or four 
months demonstrated significant improvements in the appearance of 
glabellar rhytides (frown lines).17 In response, several clinical studies 
tested the efficacy and safety of this off-label cosmetic usage of BTX-A.18 
In 2002, the FDA approved BTX-A “for the temporary improvement in 
the appearance of moderate to severe glabellar lines” (brow furrow) in 
adult patients. 19 
 Clostridium Botulinum, the bacterium responsible for the foodborne 
botulism observed by Kerner, has “eight serotypes (A, B, C α, C β, D, E, 
                                                                                                                      
13 Frank J. Erbguth & Markus Naumann, Historical Aspects of Botulinum Toxin: Justinus 
Kerner (1786–1862) and the “Sausage Poison,” 52 Neurology 1850, 1850--51 (1999). 
14 See Alan B. Scott, Development of Botulinum Toxin Therapy, 22 Dermatologic Clinics 
131, 131(2004). 
15 See Frank J. Erbguth, Botulinum Toxin, a Historical Note, 351 Lancet 1820, 1820 
(1998) (citing Justinus Kerner, Das Fettgift oder die Fettsäure und ihre Wirkung 
auf den Tierischen Organismus ein Beytrag zur Untersuchung des in Verdor-
benen Würsten Giftig Wirkenden Stoffes (F.R.G.) (Stuttgart-Tübingen, Cotta 1822)). 
16 See Scott, supra note 14, at 132. 
17 See id. 
18 See J. Alastair Carruthers et al., A Multicenter, Double-Blind, Randomized, Placebo-
Controlled Study of the Efficacy and Safety of Botulinum Toxin Type A in the Treatment of Glabellar 
Lines, 46 J. Am. Acad. Dermatology 840, 841 (2002); Monte S. Keen et al., Botulinum 
Toxin A for Hyperkinetic Facial Lines: Results of a Double-Blind, Vehicle-Controlled Study, 94 Plas-
tic & Reconstructive Surgery 94, 94–99 (1994); Nicholas J. Lowe et al., Botulinum A 
Exotoxin for Glabellar Folds: A Double-Blind, Vehicle-Controlled Study with an Electromyographic 
Injection Technique, 35 J. Am. Acad. Dermatology 569, 572 (1996). 
19 Press Release, Allergan Pharms., Allergan’s Botox Cosmetic Receives Approval by the 
FDA for the Treatment of Glabellar Lines (Brow Furrow) (Apr. 15, 2002), available at http:// 
agn.client.shareholder.com/releasedetail.cfm?ReleaseID=82518. Allergan manufactures and 
distributes BTX-A separately as Botox and Botox Cosmetic to distinguish between BTX-A’s 
cosmetic and therapeutic indications. See id. Unless otherwise noted in this commentary, 
Botox will refer to BTX-A for cosmetic indications. 
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F, and G) that produce seven . . . distinct neurotoxins.”20 Each serotype 
shares the ability to block acetylcholine from being released in striated 
muscles, which causes chemical denervation, temporary muscle paraly-
sis at the site of injection, and “smooth[es] hyperkinetic lines [facial 
wrinkles].”21 Although botulinum toxin type B has been approved by 
the FDA for therapeutic (non-cosmetic) indications,22 BTX-A is the on-
ly serotype currently approved for cosmetic use in the United States.23 
Until April 2009, Botox was the only commercially available formula-
tion of BTX-A.24 
 Achieving the correct dosage of Botox is essential to safe and effec-
tive use, and depends on the proficiency of the medical practitioner 
who is performing the injection.25 Botox is a sterile, freeze-dried form 
of BTX-A.26 It is distributed in a concentrated crystalline form, and 
must be reconstituted with saline prior to use.27 The dilution ratio of 
BTX-A to saline varies and depends on a range of factors that must be 
assessed by the injector prior to use.28 Moreover, “incorrect dosages are 
                                                                                                                      
20 Arnold W. Klein, Complications, Adverse Reactions, and Insights with the Use of Botulinum 
Toxin, 29 Dermatologic Surgery 549, 549 (2003) [hereinafter Klein, Complications, Ad-
verse Reactions, and Insights]; see Erbguth & Naumann, supra note 13, at 1850. 
21 See J. Alastair Carruthers & Jean Carruthers, Botulinum Toxin A in the Mid and Lower 
Face and Neck, 22 Dermatologic Clinics 151, 152 (2004) [hereinafter Carruthers & Car-
ruthers, Botulinum Toxin A in Face and Neck]; Arnold W. Klein, Contraindications and Compli-
cations with the Use of Botulinum Toxin, 22 Clinics in Dermatology 66, 66, 68 (2002) [here-
inafter Klein, Contraindications]. 
22 See Timothy C. Flynn, Myobloc, 22 Dermatologic Clinics 207, 207 (2004); Press Re-
lease, Elan Pharms., FDA Approves Elan’s Myobloc Botulinum Toxin Type B Injectable 
Solution (Dec. 11, 2000), available at http://ir.elan.com/phoenix.zhtml?c=88326&p=irol-
newsArticle&ID=137749&highlight=. See generally Craig Zalvan et al., Noncosmetic Uses of 
Botulinum Toxin, 22 Dermatologic Clinics 187 (2004). 
23
 See Arnold W. Klein, Complications with the Use of Botulinum Toxin, 22 Dermatologic 
Clinics 197, 198 (2004) [hereinafter Klein, Complications with the Use of Botulinum Toxin]. 
24 See J. Alastair Carruthers & Jean Carruthers, Use of Botulinum Toxin A for Facial En-
hancement, in Tissue Augmentation in Clinical Practice: Procedures and Techniques 
117, 119 (Arnold W. Klein ed., 2005) [hereinafter Carruthers & Carruthers, Botulinum Toxin 
A for Facial Enhancement]; Press Release, Ipsen & Medicis Pharms., FDA approves DysportTM 
for Therapeutic and Aesthetic Uses (Apr. 30, 2009), available at http://www.ipsen.com/arti- 
cles/investorrelations/regulatedinformation/20090430_dysport_usa_10.pdf. 
25 See Coté et al., supra note 3, at 410--11 (finding that numerous AEs related to BTX-A 
were caused by improper dilution modifications); Alan M. Mantell, Dilution, Storage, and 
Electromyographic Guidance in the Use of Botulinum Toxins, 22 Dermatologic Clinics 135, 
135 (2004). 
26 See Carruthers & Carruthers, Botulinum Toxin A for Facial Enhancement, supra note 24, 
at 119. 
27 See Carruthers & Carruthers, Botulinum Toxin A in Face and Neck, supra note 21, at 
151. 
28 See id. (concluding that adjustments should be made prior to performing injections 
in singers, musicians, and other patients who use their perioral muscles with intensity); 
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very likely to result in severe adverse effects.”29 Researchers have con-
cluded that improper dilution of BTX-A is a significant cause of unin-
tended spread of the toxin away from the site of injection, and may 
“[produce] symptoms of botulism.”30 
 In 2002, an estimated 1.1 to 1.6 million patients received Botox in-
jections in the United States.31 By 2003, Botox injections were the sec-
ond most commonly performed cosmetic procedure in North Amer-
ica.32 Contemporaneously, several prominent medical journal articles 
allayed lingering concerns over the drug’s toxicity and detrimental 
health effects.33 Physicians urged that when “[p]roperly used, the inci-
dence of complications [associated with the use of Botox] is low and 
their severity mild.”34 Additionally, they insisted that “most complica-
tions [were] related to poor injection techniques”35 and that there were 
no reported “long-term adverse effects or health hazards related to the 
use of Botox for any cosmetic indication.”36 
                                                                                                                      
Klein, Complications, Adverse Reactions, and Insights, supra note 20, at 553; Mantell, supra 
note 25, at 135. Factors influencing the dilution ratio include the anatomy of the injection 
site, patient’s prior conditions, and the patient’s occupation. See Carruthers & Carruthers, 
Botulinum Toxin A in Face and Neck, supra note 21, at 156; Klein, Complications, Adverse Reac-
tions, and Insights, supra note 20, at 553; Mantell, supra note 25, at 135. 
29 See Mantell, supra note 25, at 135. 
30 Coté et al., supra note 3, at 411; Bridget M. Kuehn, Studies, Reports Say Botulinum Toxins 
May Have Effects Beyond Injection Site, 299 JAMA 2261, 2262 (2008) [hereinafter Kuehn, Re-
ports]. Botulism is characterized by “cranial nerve dysfunction (resulting in double vision 
(diplopia), inability to control or coordinate the muscles used in speaking (dysarthia), 
and/or difficulty swallowing (dysphagia)), followed by progressive descending muscle weak-
ness or paralysis that can lead to respiratory failure and death.” Letter from Janet Woodcock, 
Dir., Ctr. for Drug Evaluation and Research, FDA, to Sidney Wolfe et al., Dir., Pub. Citizen 
(Apr. 30, 2009), available at http://www.fda.gov/downloads/Drugs/DrugSafety/Postmarket 
DrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcarePro- 
fessionals/UCM143989.pdf (citing Abrutyn, supra note 12, at 842-45). 
31 See Coté et al., supra note 3, at 408 (citing the findings of the Am. Soc’y of Aesthetic 
Plastic Surgeons). 
32 See J. Alastair Carruthers & Jean Carruthers, Botulinum Toxin-A Development and Use 
for Upper Facial Lines, in Textbook of Facial Rejuvenation: The Art of Minimally In-
vasive Combination Therapy 151, 151 (Nicholas J. Lowe ed., 2002). 
33 See Benjamin Ascher et al., A Multicenter, Randomized, Double-Blind Placebo-Controlled 
Study of Efficacy and Safety of 3 Doses of Botulinum Toxin A in the Treatment of Glabellar Lines, 51 
J. Am. Acad. Dermatology 223, 233 (2004) (concluding that BTX-A is an effective and 
safe treatment for glabellar lines); Arnold W. Klein, Complications with the Use of Botulinum 
Toxins, 45 Int’l Ophthalmology Clinics 163, 168 (2005). 
34 See Klein, Complications with the Use of Botulinum Toxin, supra note 23, at 197. 
35 See Alastair Carruthers & Jean Carruthers, Botulinum Toxin Type A for the Treatment of 
Glabellar Rhytides, 22 Dermatologic Clinics 137, 141 (2004). 
36 See Klein, Contraindications, supra note 21, at 68 (citing Peter Hambleton & A. Peter 
Moore, Botulinum Neurotoxins: Origin, Structure, Molecular Actions, and Antibody, in Hand-
book of Botulinum Treatment 17, 17–27 (A. Peter Moore ed., 1995)). 
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II. Discussion 
A. Independent Review of Adverse Event Reports Submitted to the FDA 
 In 2005, data emerged that cast grave doubt on the safety of Bo-
tox.37 A study published in the Journal of the American Academy of Derma-
tology (Coté Study) reviewed 1437 adverse events (AEs) reported to the 
FDA38 in connection with both therapeutic and cosmetic uses of BTX-
A.39 Researchers of this study set out to independently tally the number 
of serious AEs linked to BTX-A.40 They classified AEs according to the 
statutory definition outlined by Title 21 of the U.S. Code of Federal 
Regulations.41 According to this provision, an AE is defined as “[a]ny 
adverse experience occurring at any dose that results in [inter alia] . . . 
[d]eath, a life-threatening adverse experience, inpatient hospitalization 
or prolongation of existing hospitalization.”42 
 The Coté Study found that 217 of the 406 AEs related to therapeu-
tic use of BTX-A satisfied the statutory definition of “serious.”43 Of 
these, BTX-A was causally linked to twenty-eight deaths and seventeen 
seizures.44 Researchers also identified thirty-six serious AEs related to 
cosmetic use of BTX-A, including five instances of focal facial paralysis 
and dysphagia (difficulty swallowing).45 
 In explaining why the number of serious AEs was significantly 
greater for therapeutic use as opposed to cosmetic use, researchers hig-
                                                                                                                      
37 See Kuehn, supra note 30, at 2261. 
38 Coté et al., supra note 3, at 407. See generally Timothy Brewer & Graham A. Colditz, 
Postmarketing Surveillance and Adverse Drug Reactions: Current Perspectives and Future Needs, 281 
JAMA 824 (1999) (providing an overview of the FDA’s adverse event reporting system). 
The FDA receives notice of all AEs through the MedWatch reporting system. Coté et al., 
supra note 3, at 407. Manufacturers are required to report all AEs within fifteen calendar 
days of discovery. Food, Drug, and Cosmetic Act, 21 C.F.R. § 310.305 (2009). Nevertheless, 
“reporting by clinicians and others . . . remains voluntary;” therefore, “AEs reported to 
MedWatch represent only a subset of the actual number [of AEs] that occur.” Coté et al., 
supra note 3, at 408. 
39 See Coté et al., supra note 3, at 407. 
40 Id. at 407. 
41 Id. at 408 (citing 21 C.F.R. § 600.80 (2005)). 
42 21 C.F.R. § 600.80. 
43 Coté et al., supra note 3, at 409; see 21 C.F.R. § 600.80. 
44 Coté et al., supra note 3, at 409 (noting that “[a]mong the 28 deaths, 6 were attrib-
uted to respiratory arrest, 5 to myocardial infarction, 3 to cerebrovascular accident, 2 to 
pulmonary embolism, 2 to pneumonia . . . 5 to other known causes, and 5 to unknown 
causes of death”). 
45 Id. at 409, 412 tbl.II; see Raj K. Goyal, Dysphagia, in Harrison’s Principles of In-
ternal Medicine 217, 217 (16th ed. 2005) (defining dysphagia as “a sensation of ‘stick-
ing’ or obstruction of the passage of food through the mouth, pharynx, or esophagus”). 
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hlighted the differences between the clinical characteristics of therapeu-
tic and cosmetic cases.46 Notably, for therapeutic cases, “doses were 
higher . . . and patients tended to have serious underlying diseases.”47 By 
contrast, patients receiving cosmetic BTX-A injections “typically had no 
underlying disease reported, and [they] were injected with much small-
er doses.”48 
 More significantly, the Coté Study emphasized that many AEs tied 
to cosmetic injections were caused by a “lack of adherence to [basic] 
precepts” of BTX-A use: “[c]areful attention to drug dose, dilution, 
handling, storage, and site of injection.”49 In more than a dozen cos-
metic cases, patients were injected with five times the maximum labeled 
dosage of BTX-A.50 Researchers also found that many cosmetic injec-
tions deviated from the labeled dilution procedure.51 In fact, “[d]rug 
dilution modifications were reported frequently with such diluent sub-
stitutions as bupivacaine, lidocaine, water, and previously reconstituted 
[BTX-A], rather than the recommended saline diluent.”52 In a similar 
vein, common handling errors included “injecting reconstituted prod-
uct after the recommended 4-hour expiration, freezing or refrigerating 
reconstituted product for future use, [and] injecting multiple patients 
with [BTX-A] from a vial labeled for single-patient use.”53 
B. EMEA Warnings Regarding Adverse Reactions to BTX-A and BTX-B 
 The EMEA has implemented its own adverse reactions reporting 
system since 2004.54 Medicines meeting the EMEA’s standards of quality, 
safety, and efficacy are granted Marketing Authorization after undergo-
ing review by the Committee for Medicinal Products for Human Use 
(CHMP).55 Once Marketing Authorization has been granted, the CHMP 
publishes a European Public Assessment Report (EPAR), which details 
“the reasons for its opinion in favour of granting authorisation.”56 In 
                                                                                                                      
46 See Coté et al., supra note 3, at 409. 
47 Id. 
48 Id. 
49 Id. at 410. 
50 See id. at 410--11. 
51 Id. at 411. 
52 See Coté et al., supra note 3, at 411. 
53 Id. 
54 See 2004 O.J. (L 136) 12; Pub. Citizen Health Res. Group, supra note 4 (recognizing 
the EMEA’s system as the counterpart to the FDA’s MedWatch reporting system). 
55 See 2004 O.J. (L 136) ¶¶ 13, 23. 
56 Id. ¶ 3. 
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addition, EPARs contain a Summary of Product Characteristics (SPC).57 
On botulinum toxin products, the SPC includes a “‘[s]pecial warnings 
and precautions for use’ section that succinctly addresses all the major 
issues related to migration of [the] injected drug.”58 All EPARs are writ-
ten “in a manner that is understandable to the public” and are pub-
lished on the EMEA’s website.59 
 In March of 2005, the CHMP updated its SPC for Neurobloc 
(BTX-B) after an interim analysis found that thirty percent of the total 
number of adverse reactions60 reported to the EMEA between January 
2001 and December 2003 satisfied the EMEA’s definition of “serious.”61 
Mirroring the conclusion reached by the Coté Study with respect to 
BTX-A-related AEs reported to the FDA, the CHMP found that most 
adverse reactions associated with BTX-B were caused by spread of the 
toxin beyond the injection site.62 
 Eight months later, the CHMP issued a second, more robust, advi-
sory. 63 European health officials announced that they had discovered 
evidence linking BTX-B to the deaths of seventeen patients in Europe.64 
Furthermore, the CHMP clarified that the reported negative side effects 
were “not specific of [BTX-B] but of the whole class [of botulinum tox-
ins].”65 In connection with this finding, the updated EPAR warned pa-
tients of an “overall concern on the class of botulinum toxins regarding 
dysphagia and fatal outcomes.”66 The EMEA further responded by re-
quiring BTX-B manufacturers to package an updated set of warning 
leaflets along with every drug vial, explaining how patients should be 
                                                                                                                      
57 See id.; Pub. Citizen Health Res. Group, supra note 4. 
58 See Pub. Citizen Health Res. Group, supra note 4. 
59 2004 O.J. (L 136) ¶ 3; see, e.g., Eur. Meds. Agency, Procedural Steps Taken and Scien-
tific Information After the Authorisation: Changes Made After 01/02/2004, 1, http://www. 
emea.europa.eu/humandocs/PDFs/EPAR/neurobloc/H-301-en8b.pdf (last visited Apr. 15, 
2010) [hereinafter EMEA, Procedural Steps]. 
60 EMEA, Procedural Steps, supra note 59, at 7, 8. 
61 See 2001 O.J. (L 83) ¶ 12. European Community Regulations define “serious adverse 
reaction” as “a reaction which results in death, is life-threatening, requires inpatient hospi-
talisation or prolongation of existing hospitalisation, results in persistent or significant 
disability or incapacity, or is a congenital anomaly/birth defect.” Id. 
62 Compare Coté et al., supra note 3, at 410 (concluding that the majority of AEs re-
ported to the FDA in connection with BTX-A were caused by distant spread of the toxin), 
with EMEA, Procedural Steps, supra note 59, at 4 (concluding that most adverse effects 
reported to the EMEA in connection with BTX-B were caused by distant spread of the 
toxin). 
63 See EMEA, Procedural Steps, supra note 59, at 5. 
64 Id. 
65 See id. 
66 See id. at 4--5. 
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given BTX-B, and warning against the possibility of serious adverse ef-
fects caused by the spread of the toxin from the site of injection.67 
C. The FDA’s Response to Calls for Stronger Patient Warnings 
 Heeding the EMEA’s call for an aggressive stance toward botuli-
num toxin products, regulatory agencies in the United Kingdom and 
Germany “amplified the EU[’s] warning[s] [by requiring manufactur-
ers to issue] ‘Dear Doctor Letters’” that “alert[ed] physicians in its 27 
member states about the need to monitor for signs of botulinum toxin 
adverse events.”68 Despite the Coté Study’s somber findings, however, 
“no similar official warnings [were issued] by the FDA [in the United 
States].”69 Responding to government inaction in the United States, in 
January 2008, Public Citizen Health Research Group (Public Citizen) 
sent a letter to FDA Commissioner Andrew von Eschenbach petitioning 
the Agency to take stronger measures to warn patients of the dangers 
associated with BTX-A and BTX-B.70 Using the EMEA’s EPAR advisory 
system as a model for reform, the petition set forth three basic recom-
mendations for protocol change.71 
 First, the petition called for clearer, more stream-lined, physician-
directed warnings.72 Unlike the warnings issued by the EMEA, in the 
United States, information for physicians was “scattered throughout the 
labels,” or obliquely listed under an “Adverse Reactions” section.73 In 
response, Public Citizen requested a concise description of “all major 
issues related to migration of the injected drug.”74 The petition also 
requested that the FDA clarify that “the phenomenon of distant spread 
is not restricted to patients [undergoing therapeutic BTX-A treat-
ment]” but equally applies to cosmetic use of BTX-A.75 
 Second, Public Citizen called for a clear and consistent set of pa-
tient-directed warnings.76 In the United States, only a fraction of drugs 
possess patient-friendly labels that provide complete and accessible in-
                                                                                                                      
67 Public Citizen Health Res. Group, supra note 4. 
68 See id. 
69 See id. 
70 See Food, Drug, and Cosmetic Act, 21 C.F.R. § 10.30 (2009) (outlining the adminis-
trative procedure for citizen petitions to the FDA). See generally Pub. Citizen Health Res. 
Group, supra note 4. 
71 See generally Pub. Citizen Health Res. Group, supra note 4. 
72 See id. 
73 See id. 
74 See id. 
75 See id. 
76 See id. 
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formation regarding adverse effects.77 For BTX-A products in particular, 
“the ‘Information for Patients’ section [was] very brief, and [did] not 
approach the five-page EU patient information in [terms of] compre-
hensiveness.”78 For example, on the label then-existing for Botox, the 
only information provided “was that ‘[p]atients or caregivers should be 
advised to seek immediate medical attention if swallowing speech or 
respiratory disorders arise.’”79 The labeling also failed to consistently 
advise patients of the health risks posed by distant spread of the toxin.80 
 Third, the petition urged the FDA to require “detailed written in-
formation in the form of FDA-approved Medication Guides” to be dis-
pensed by the physician at the time the drug is injected into the pa-
tient.81 In this respect, Public Citizen addressed the concern that 
“[e]ven if [the] . . . labeling [was] more complete, there [was] no evi-
dence that physicians [would] actually discuss [the] information with 
their patients.”82 
 In April of 2009, the FDA responded to Public Citizen’s petition by 
granting all three of its requests for protocol reform.83 The Agency noti-
fied all Biologics License Application (BLA) holders for botulinum tox-
in products that “the risk of spread of botulinum toxin effects from the 
site of injection should be included in the labeling of the products (in-
cluding a boxed warning).”84 Additionally, the FDA sent notification 
letters to BLA holders advising that a “Risk Evaluation and Mitigation 
Strategy (REMS) . . . is necessary to ensure that the benefits of these 
products outweigh the risks.”85 Lastly, it required that every REMS must 
include “a Medication Guide and Communication Plan, including a 
Dear Health Care Provider letter, and a timetable for submission of as-
sessments.”86 
III. Analysis 
 The FDA’s improved warning protocol vis-à-vis BTX-A represents a 
considered response to Public Citizen’s criticism that the Agency lagged 
                                                                                                                      
77 See Pub. Citizen Health Res. Group, supra note 4. 
78 See id. 
79 Id. 
80 Id. 
81 Id. 
82 Id. 
83
 See generally Woodcock, supra note 30 (providing the FDA’s response to Public Citi-
zen’s petition). 
84 Id. at 1. 
85 Id. 
86 Id. 
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behind its European counterpart.87 Like the Summary of Product Char-
acteristics accompanying every EPAR, the FDA’s new BTX-A labeling 
requirements include a strengthened “Warnings and Precautions” sec-
tion that provides a stream-lined advisory regarding the spread of botu-
linum toxin effects beyond the site of injection.88 The FDA-required 
physician-distributed Medication Guides mimic the “Package Leaflet: 
Information for the User” pamphlets accompanying botulinum toxin 
products distributed in the EU.89 Both publications are “additional me-
thod[s] of communicating the signs and symptoms of the spread of bo-
tulinum toxin effects” and “can help ensure that the patient or caregiver 
is aware of and can self-monitor for serious risks.”90 Finally, the FDA-
mandated “Dear Health Care Professional” letters—considered a mini-
mum component of the FDA’s REMS communication program—are 
functionally similar to the “Dear Doctor Letters” required by regulatory 
agencies in the United Kingdom and Germany.91 
 The FDA’s bolstered warning protocol may raise public awareness 
of the health risks posed by botulinum toxins.92 Nevertheless, it is un-
clear whether this protocol will reduce the number of serious AEs 
linked to BTX-A.93 Despite reports by mainstream media of BTX-A re-
lated deaths, the number of Botox injections performed in the United 
States rose by eight percent in 2008.94 This statistic offers compelling 
                                                                                                                      
87 See Pub. Citizen Health Res. Group, supra note 4. See generally Woodcock, supra note 
30 (outlining the FDA’s improved warning protocol vis-à-vis botulinum toxins). 
88 See Eur. Meds. Agency, Neurobloc: Summary of Product Characteristics 3, 5, 
http://www.emea.europa.eu/humandocs/PDFs/EPAR/neurobloc/emea-combined-h301en. 
pdf (last visited Apr. 15, 2010) [hereinafter EMEA, BTX-B SPC]; Woodcock supra note 30, at 
14, 15. 
89 See EMEA, BTX-B SPC, supra note 88; Woodcock, supra note 30. 
90 Woodcock, supra note 30, at 17; see EMEA, BTX-B SPC, supra note 88, at 26–28. 
91 See Woodcock, supra note 30, at 17–18; Letter from Bundesinstitut für Arzneimittel 
und Medizinprodukte to Prescribing Physicians ( June 2007), available at http://www.bfarm. 
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and Healthcare Prods. Reg. Agency to Prescribing Physicians ( June 2007), available at http:// 
www.mhra.gov.uk/home/groups/es-era/documents/websiteresources/con2031672.pdf. 
92See Pub. Citizen Health Res. Group, supra note 4 (concluding that “failure to imme-
diately [implement the strengthened warning protocol] is likely to result in more prevent-
able serious adverse reactions and deaths from [botulinum toxin] products”). 
93 See Am. Soc’y of Plastic Surgeons (ASPS), 2009 Report of the 2008 Statistics 
5 (2009), available at http://www.plasticsurgery.org/Media/stats/2008-US-cosmetic-recon- 
structive-plastic-surgery-minimally-invasive-statistics.pdf (last visited Apr. 15, 2010). 
94 Id.; see, e.g., Gardiner Harris, Group Seeks New Warning About Botox, N.Y. Times, Jan. 
25, 2008, at A19. 
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evidence that the U.S. Botox market may be unwilling to part with the 
drug’s wrinkle-reducing effects.95 
 For a stalwart population of U.S. patients receiving Botox injec-
tions, a heightened warning protocol alone may not provide a practical 
strategy for minimizing the incidence of complications.96 Although the 
new warning protocol obligates BTX-A manufacturers to provide pa-
tients with a clearer list of complications caused by the distant spread of 
the toxin, the FDA has not required manufacturers to educate patients 
or caregivers about why distant spread occurs or ways to prevent it.97 
FDA Director Janet Woodcock conceded this point in her response to 
Public Citizen’s petition: “[a]lthough we do not currently have recom-
mendations for how to prevent these events, it is essential that the po-
tential for distant spread of toxin effects be considered in assessing the 
risks and benefits of using botulinum toxin products.”98 
 In order to reduce the number of serious AEs linked to BTX-A, it 
may be necessary for officials to identify the cause of distant spread, 
and require manufacturers to educate caregivers and patients about 
ways to prevent it.99 The Coté Study made substantial contributions to 
the first step of this proposal.100 In that study, researchers concluded 
that distant spread of botulinum toxins frequently occurred when prac-
titioners ignored fundamental precepts of BTX-A usage: proper han-
dling, storage, dilution, and injection of BTX-A.101 If this conclusion is 
correct, minimum training requirements and additional guidelines 
with respect to BTX-A injection practices may be necessary in order to 
reduce the number of AEs related to BTX-A.102 
 The power to regulate medical practices, however, falls squarely 
outside of the FDA’s authority.103 In the United States, the FDA’s drug 
approval power is governed by the Food, Drug, and Cosmetic Act.104 
                                                                                                                      
95 See ASPS, supra note 93, at 5. 
96 See id. 
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98 Woodcock, supra note 30, at 14–15. 
99 See Coté et al., supra note 3, at 410. 
100 See id. 
101 See id. at 410–11. 
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103 Id. at 408 (concluding that “[t]he FDA does not have authority to control decisions 
made by qualified health care practitioners . . . or to otherwise regulate medical or surgical 
practice”). 
104 21 U.S.C. § 355 (2006); Rebecca Dresser & Joel Frader, Off-Label Prescribing: A Call 
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Once the FDA approves a drug for a particular use, it issues a “specific 
label [that] includes information about approved indications for prod-
uct use, as well as the approved dosage, method of administration and 
patient population.”105 Nevertheless, “[o]nce a drug . . . has been ap-
proved or cleared . . . health-care professionals may lawfully use or pre-
scribe that product for uses or treatment regimens that are not in-
cluded in the product’s approved labeling.”106 The FDA’s refusal to 
monitor and restrict such “off-label” uses has been interpreted by the 
U.S. Supreme Court as “a necessary corollary of the FDA’s mission to 
regulate [medicine] without directly interfering with the practice of 
medicine.”107 
 In contrast, states retain broad latitude to define and regulate the 
practice of medicine.108 Many states have medical boards that are re-
sponsible for overseeing medical practices, and are authorized to 
promulgate rules, license practitioners and conduct disciplinary pro-
ceedings.109 Despite this fact, states have similarly struggled to arrive at 
an adequate solution to the problem of improper BTX-A medical prac-
tices.110 
 Physicians representing national boards of plastic surgeons and 
dermatologists have disagreed over what training physicians should be 
required to undergo in order to perform minimally invasive cosmetic 
                                                                                                                      
105 Dresser & Frader, supra note 104, at 477. 
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110 See, e.g., Paul Harasim, Proposed Rules Clarify What Medical Assistants Can, Can’t Do, 
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lation, Las Vegas Sun, Sept. 18, 2009, http://www.lasvegassun.com/news/2009/sep/18/ 
medical-board-adopts-emergency-botox-regulation. 
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procedures such as Botox injections.111 State medical boards, however, 
have grappled with an even more basic issue: whether licensed non-
physician practitioners, such as nurses and physicians assistants, should 
be allowed to perform Botox injections.112 Among those states that do 
permit licensed non-physician practitioners to perform Botox injec-
tions, there is wide disagreement about the level of oversight that must 
be invested by supervising physicians.113 In other states, there remains a 
lingering debate about whether unlicensed non-physician practitioners, 
such as medical assistants, should be allowed to administer Botox.114 
Conclusion 
 Justinus Kerner first warned that harnessing the benefits of botuli-
num toxins would require future practitioners to overcome the inherent 
difficulties of handling the toxins in a clinical setting. Kerner’s prognos-
tic commentary from over a century ago offers surprising insight into a 
dilemma that currently grips the cosmetic medicine industry. 
 The FDA’s strengthened labeling requirements and Risk Evaluation 
and Mitigation Strategy, which mirrors the European Medicines Agen-
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cy’s European Public Assessment Report system, represents a positive 
step toward raising public awareness of the health risks related to botu-
linum toxins. Nonetheless, for a U.S. cosmetic medicine market that 
appears unwilling to part with the aesthetic benefits offered by products 
such as Botox, it is doubtful that this improved protocol, tout court, will 
reduce the number of serious adverse events linked to BTX-A. 
 Following Kerner’s advice, a reduction in the number of adverse 
events requires that practitioners surmount the dangers attendant to 
clinical BTX-A use. As the Coté Study suggests, this means practitioners 
must follow well-established precepts of BTX-A use, including proper 
handling, storage, dilution, and injection. Although regulatory action 
to that effect falls outside of the FDA’s authority, it remains available to 
the states and their respective medical boards. 
